US7413862B2 - FRET probes and methods for detecting interacting molecules - Google Patents
FRET probes and methods for detecting interacting molecules Download PDFInfo
- Publication number
- US7413862B2 US7413862B2 US11/122,776 US12277605A US7413862B2 US 7413862 B2 US7413862 B2 US 7413862B2 US 12277605 A US12277605 A US 12277605A US 7413862 B2 US7413862 B2 US 7413862B2
- Authority
- US
- United States
- Prior art keywords
- probes
- probe
- molecular
- reactive group
- molecular probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 239000000523 sample Substances 0.000 title claims abstract description 272
- 238000000034 method Methods 0.000 title claims abstract description 72
- 238000002866 fluorescence resonance energy transfer Methods 0.000 title claims description 65
- 238000012546 transfer Methods 0.000 claims abstract description 51
- 239000000975 dye Substances 0.000 claims description 124
- 239000003068 molecular probe Substances 0.000 claims description 63
- 230000027455 binding Effects 0.000 claims description 56
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 25
- 229960002685 biotin Drugs 0.000 claims description 23
- 235000020958 biotin Nutrition 0.000 claims description 23
- 239000011616 biotin Substances 0.000 claims description 23
- 150000002632 lipids Chemical class 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 108090001008 Avidin Proteins 0.000 claims description 12
- 238000000684 flow cytometry Methods 0.000 claims description 12
- 239000002771 cell marker Substances 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 7
- 238000010186 staining Methods 0.000 claims description 7
- 108010004469 allophycocyanin Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 3
- 108060006184 phycobiliprotein Proteins 0.000 claims description 3
- 239000012099 Alexa Fluor family Substances 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000002096 quantum dot Substances 0.000 claims description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 80
- 235000018102 proteins Nutrition 0.000 description 75
- 102000004169 proteins and genes Human genes 0.000 description 75
- 230000003993 interaction Effects 0.000 description 49
- 238000001514 detection method Methods 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 238000002372 labelling Methods 0.000 description 13
- 230000008045 co-localization Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000021615 conjugation Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 108010042653 IgA receptor Proteins 0.000 description 6
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 150000003141 primary amines Chemical class 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000004001 molecular interaction Effects 0.000 description 5
- 239000002853 nucleic acid probe Substances 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000006916 protein interaction Effects 0.000 description 4
- 230000004850 protein–protein interaction Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- -1 glycoconjugates Proteins 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108010038196 saccharide-binding proteins Proteins 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000003335 steric effect Effects 0.000 description 3
- 101710159080 Aconitate hydratase A Proteins 0.000 description 2
- 101710159078 Aconitate hydratase B Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 2
- 102000001183 RAG-1 Human genes 0.000 description 2
- 108060006897 RAG1 Proteins 0.000 description 2
- 102000015097 RNA Splicing Factors Human genes 0.000 description 2
- 108010039259 RNA Splicing Factors Proteins 0.000 description 2
- 101710105008 RNA-binding protein Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 102000036646 Signalosomes Human genes 0.000 description 2
- 108091007411 Signalosomes Proteins 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 238000002292 fluorescence lifetime imaging microscopy Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 108091006050 fluorescent recombinant proteins Proteins 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000009878 intermolecular interaction Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000004576 lipid-binding Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical class C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- BPVHBBXCESDRKW-UHFFFAOYSA-N 5(6)-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21.C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BPVHBBXCESDRKW-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102100029951 Estrogen receptor beta Human genes 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108010010522 Phycobilisomes Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 1
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000186983 Streptomyces avidinii Species 0.000 description 1
- 102000008685 T Cell Transcription Factor 1 Human genes 0.000 description 1
- 108010088184 T Cell Transcription Factor 1 Proteins 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000034435 immune system development Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 102000026415 nucleotide binding proteins Human genes 0.000 description 1
- 108091014756 nucleotide binding proteins Proteins 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 210000002306 phycobilisome Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 238000010379 pull-down assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000008960 regulation of mRNA stability Effects 0.000 description 1
- 230000006803 regulation of nuclear mRNA splicing, via spliceosome Effects 0.000 description 1
- 230000024769 regulation of transport Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
Definitions
- This invention relates generally to biotechnology, and more particularly to the field of detecting interacting proteins and other closely associated molecules. More specifically, the invention relates to assessing close interactions between macromolecules at the single cell level.
- Co-localization studies are often employed to monitor the proximity of one protein of interest to another protein of interest.
- Co-localization data are also useful as a means of evaluating protein information inferred from genetic data, for instance, supporting or refuting putative protein interactions suggested from for example a yeast two-hybrid analysis.
- Co-localization of intracellular proteins can be assessed by use of differentially labeled antibodies specifically reactive with endogenous proteins of interest which can be visually detected by fluorescence microscopy via immunofluorescence.
- fixed cells are treated first with a set primary antibodies specific to proteins of interest, and then with a set of secondary antibodies conjugated with fluorescent dye.
- Antibodies directly conjugated with a fluorescent dye may also be used.
- dyes should differ in excitation and emission wavelength, so that they can be excited independently and observed in separate fluorescent channels.
- genes encoding the proteins of interest may be fused to a reporter gene encoding a reported protein, like green fluorescent protein (GFP), or tagged with an epitope, such as Myc or HA. Reporters and epitope tags are fused routinely to either the N or C termini of target genes.
- Dyes specific to membranes or nucleic acids may additionally be used to reveal the cell organelles, for instance, the nucleus can be visualized by DNA staining with DAPI. Images are generally collected on a confocal microscope which ensures that observed proteins are in the same focal plane, and therefore co-localization, if any, is real. Co-localization is revealed by overlap in colors.
- Co-localization of cell surface molecules for example, proteins A and B
- a clump or patch of protein A molecules assembles in the membrane. If the cell is alive and metabolizing actively, patches are formed which can further assemble into a cap in a process called “capping”, preferably occurring at 37 degrees Celsius.
- the patches/cap can be stained by indirect fluorescence staining procedures. Subsequently, cells may be counterstained at 4 degrees Celsius (to retain the patches/cap) with a dye-conjugated antibody against protein B to evaluate whether protein B has moved together i.e.
- FRET fluorescence resonance energy transfer
- a dye called a “donor” transfers, after excitation by a light source, its energy to another dye (called “acceptor”).
- acceptor Another dye
- the energy transfer occurs when the emission spectrum of the donor dye overlaps significantly with the excitation spectrum of the acceptor.
- Sufficiently close juxtaposition of the two dyes generally closer than 100 ⁇ ngstrom, but preferably closer than 50 ⁇ ngstrom, is essential for energy transfer between the donor/acceptor pair.
- One ⁇ ngstrom a metric unit of length, is equal to 0.1 nanometer or 10 ⁇ 10 meter.
- FRET is usually based on the interaction between donor and acceptor dyes that are both fluorescent.
- FRET can also be detected by the quenching of donor fluorescence using a nonfluorescent acceptor dye.
- Nonfluorescent acceptor dyes are in general advantageous because they eliminate the background fluorescence that results from direct acceptor excitation.
- use of a nonfluorescent acceptor involves measuring a decrease in donor fluorescence. Generally, detection of a decreased signal is less sensitive compared to detection of an increased signal. Therefore, a method according to the invention is preferably practiced using a fluorescent donor and a fluorescent acceptor dye.
- FRET energy transfer efficiency is inversely proportional to the sixth power of the distance between the donor and the acceptor.
- FRET first described by Förster, has become extremely important for modern cell biology because FRET allows to measure distances between molecules on a scale of a few nanometers. This is far below the resolution limit of modern optical far field microscopy, which currently is at approximately 100 nm.
- FRET technology has been used for detection of various individual (bio)molecules.
- U.S. Pat. No. 6,235,535 discloses a fluorescence-based immunoassay method for the detection of an analyte in a biological sample.
- the method is based on the ability of a multivalent analyte (antigen) to induce aggregation of identical receptor molecules (antibodies) labeled with a fluorophore, which molecules are immobilized onto yet freely mobile on a lipid membrane. Antigen-induced aggregation of the receptors causes FRET to take place. Also in U.S. patent Publication 2002/0081617, antibodies directed to the same epitope but labeled with either a donor of acceptor dye are immobilized, in this case onto beads. Upon addition of an analyte (antigen) of interest, the analyte functions as a bridge and brings a pair of antibodies into close proximity of each other which leads to FRET. Thus, U.S. Pat. No.
- FRET Fluorescence Activated FRET
- the extreme sensitivity of the FRET process on the distance between molecules renders it a very useful tool for the resolution of intracellular protein arrangements and protein dynamics.
- the presence of FRET indicates intermolecular interaction since it is observable only for nanometer-scale fluorophore distance. This implies in particular that simple co-localization of two molecules, e.g. proteins, is not sufficient to yield energy transfer.
- FRET is a technique that can give clear, unambiguous answers to questions about protein-protein interactions. FRET measurements can be used to determine protein interactions at the cell surface 2 .
- FRET technology was also used in a highly specific fluorescence lifetime imaging microscopy (FLIM) method for monitoring epidermal growth factor receptor (EGFR) phosphorylation in cells.
- FLIM fluorescence lifetime imaging microscopy
- fluorescently tagged proteins have proven to be very useful, they do have limitations, such as their significant size (>200 amino acids). Also, the overall folding and tertiary structure of a tagged protein may be different from that of the native, non-tagged protein. This may result in different, erroneous interactions with other molecules. Drawing conclusions with respect to the addressed protein-protein interactions on the basis of FRET data between pairs of tagged proteins, as well as performing comparisons with normal cellular functions in living cells, is justified only if the recombinant, tagged proteins behave similar to the corresponding endogenous wild-type proteins.
- the expressed fluorescently-tagged protein should reveal the same intracellular distribution as the wild-type protein; the expression of the tagged protein per se should not induce or inhibit cellular functions and the tagged protein expressed in the cell should not create significant background FRET-signal, for example, due to overexpression, pH shift etc.
- Another major drawback of the use of recombinant, tagged proteins lies in the fact that it requires transfection or co-transfection of a chimeric construct or constructs of interest into a cell and selection of a cell showing adequate expression of a construct to yield a functional protein. Such a system does not allow detection of an endogenous protein and can therefore not be used to evaluate endogenous interacting molecules.
- a pair of antibody conjugates was used to study cell surface proteins on human lymphocytes: the CD8alpha chain detected by pairs of antibodies against different epitopes; the very late antigen 4 (VLA4), a heterodimeric alpha 4 beta 1 integrin, was detected via FRET between antibody conjugate pairs specific for either integrin beta 1 (CD29) or integrin alpha 4 (CD49d); association of T-cell receptor (TCR) with a soluble antigen ligand was detected by FRET when anti-TCR antibody and MHC class I/peptide complexes were used.
- VLA4 very late antigen 4
- TCR T-cell receptor
- TCR T-cell receptor
- MHC class I/peptide complexes were used.
- antibody mediated FRET technology was used to measure the interaction of c-kit receptor with its ligand SCF (stem cell factor). 7 Thus far, antibody-mediated FRET technology has not been applied to detect intracellular protein-protein interactions.
- FRET technology has also been applied for the detection of a protein-DNA interaction on the basis of a so-called indirect binding principle. For example, it was used to monitor the interaction between the p65 subunit of the transcription factor, NF-kappaB and its DNA binding site.
- NF-kappaB is of great relevance to the pharmaceutical sector due to its ability to regulate a number of genes involved in various immune and inflammatory responses. As such NF-kappaB has been implicated in several disease states including various viral infections (HIV), arthritis and cancer.
- An anti-GST antibody labeled with Cy3 (approx. 7-12 dyes per molecule) is allowed to interact with an affinity purified GST fusion protein of p65 and GST (p65GST).
- dsDNA double-stranded DNA sequence which contains the NF-kappaB binding site was singly labeled with Cy5 at the 5′ end of the coding sequence. This was then incubated with a Cy3 labeled antibody and p65GST. The reaction was done either in the presence or absence of unlabeled non-specific or specific competitor dsDNA. In the absence of either competitor, binding by p65-GST resulted in FRET between the Cy3 donor molecules on anti-GST and Cy5 acceptor molecule on dsDNA.
- the present invention provides the insight that dye-conjugated probes, for instance, antibodies, can be used to detect interacting endogenous molecules when these probes are sufficiently juxtaposed.
- a molecular probe is capable of specifically binding to an interacting molecule of interest via its so-called binding domain.
- a reactive group can be used to modulate juxtapositioning of the probes.
- a reactive group has no or a minimal tendency to compete with the binding domain for binding to an interacting molecule.
- a set of probes of the invention can be distinguished from known sets of antibody probes which are clustered or juxtaposed by the mere binding to one antigenic molecule or complex.
- a reactive group preferably remains available for modulating the spatial organization of juxtaposed probes after the probes are bound to interacting molecules.
- the invention provides a method for detecting at least two interacting molecules in a cell using a set of at least a first and a second molecular probe, each probe capable of binding to a different molecule, each probe further provided with a dye wherein the dyes together allow energy transfer, at least one probe provided with a reactive group allowing to modulate juxtaposing of the at least first and the second probe such that there is an increased likelihood of energy transfer between the dyes, comprising providing a set of probes, providing a sample comprising a cell, contacting the sample with the probes under conditions that allow juxtaposing of the probes on the interacting molecules, removing any unbound and any non-specifically bound probe and detecting juxtaposition of the probes via FRET to determine the interaction between the molecules.
- a suitable probe is a substance capable of specifically binding to a specific molecule.
- a specific molecule may be a protein, nucleic acid, lipid, carbohydrate.
- a nucleic acid may be DNA or RNA.
- a probe can be a conventional (poly- or monoclonal) or a synthetic antibody or a binding fragment functionally equivalent thereto, such as a Fab′, Fab or a single chain Fv fragment.
- a probe according to the present invention in fact comprises any type of binding molecule capable of specifically binding to or hybridizing with a specific molecule such as a protein, a nucleic acid, a lipid molecule, a carbohydrate moiety or another class of biomolecules.
- the invention can be practiced with a nucleic acid probe capable of hybridizing to a specific nucleic acid sequence.
- Various nucleic acid probes can be used in the invention to identify genetic elements. These include traditional probes such as small strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) as well as a peptide nucleic acid (PNA).
- PNA is related to, but distinct from, DNA.
- the chemical structure of PNA differs from DNA in that a peptide-like backbone instead of a phosphate backbone, supports the nucleic acid bases.
- Nucleic acid probes to be used according to the invention can be selected on the basis of sequence analysis of nucleic acid regions to be investigated. The probes can be synthesized and labeled according to methods known in the art. Successful binding of a probe to a nucleic acid region within a sample identifies the gene segment.
- the term dye refers to a substituent which, in concert with another dye, can be used for energy transfer e.g. FRET analysis. It is preferred that at least one of the dyes is a fluorochrome.
- a donor dye molecule must absorb light and transfer it through the resonance of excited electrons to a second dye molecule, the acceptor.
- the fluorescence emission wavelength of the donor must be lower than the excitation wavelength of the acceptor; that is, the process must be energetically “downhill”.
- FRET is usually based on the interaction between donor and acceptor dyes that are both fluorescent
- nonfluorescent acceptor dyes may also be used. These can sometimes be advantageous because they eliminate the background fluorescence that results from direct (i.e., nonsensitized) acceptor excitation.
- fluorochromes examples include fluorescein labels, for instance, 5-(and 6)-carboxyfluorescein, 5- or 6-carboxyfluorescein, 6-(fluorescein)-5-(and 6)-carboxamide hexanoic acid and fluorescein isothiocyanate, Alexa Fluor dyes, cyanine dyes such as Cy2, Cy3, Cy5, Cy7, optionally substituted coumarin, R-phycoerythrin, allophycoerythrin, Texas Red and Princeston Red as well as conjugates of R-phycoerythrin and, e.g. Cy5 or Texas Red. See also the website located at probes.com/handbook/tables/1570.html.
- Other dyes of interest are quantum dot dyes, which come in a nearly unlimited palette of colors.
- Suitable dyes are those suitable for analysis by conventional flow cytometry. FRET pairs which can be used for detection by most conventional flow cytometers are discussed in, for example, Szollosi et al. 8 Preferred combinations of fluorochromes for practicing the present invention comprise those dyes used in the classical tandem conjugates, also referred to as duochromes 9 .
- a sample is contacted with two antibodies, one against protein A and the other against protein B to monitor an interaction between protein A and protein B.
- One antibody is labeled with a FRET donor dye and the other with a FRET acceptor dye. Only when protein A is in close proximity of protein B, e.g. when both are part of a larger protein complex, the two antibodies become sufficiently close together (“juxtaposed”) which allows the donor/acceptor pair to induce a detectable FRET fluorescence signal.
- a complete antibody is a large Y-shaped protein molecule, ⁇ 150 kDa in size, made up of 2 heavy chains and 2 light chains.
- antibody molecules can bridge a relatively large distance.
- the flexibility of an antibody may decrease the probability of energy transfer between a pair of dyes that are conjugated to juxtaposed antibody probes.
- the size of a probe or a dye might interfere with energy transfer via exerting negative steric effects.
- a dye conjugate like a fluorescent probe, it is in general not possible to control the site of conjugation. In case of antibody conjugation, a dye moiety can become attached to different parts of the antibody molecule.
- the spatial orientation of dyes on probes can be favorable or unfavorable for energy transfer efficiency, i.e., dyes attached to probes need not necessarily be within energy transfer distance of each other.
- FRET was detected in all cases albeit that the energy transfer efficiency observed was always less than 10%. Possibly, this was due to steric effects associated with the size and structure of PE and APC.
- FRET probes are close juxtapositioning of FRET probes
- FIG. 1 is a schematic diagram of the principle of fluorescence resonance energy transfer (FRET) with fluorochrome X as donor dye and Y as acceptor dye.
- FRET fluorescence resonance energy transfer
- the acceptor dye Y will not be excitated by the emission light of the donor dye X, if the distance between X and Y is too large. If the distance between the donor and acceptor dye is sufficiently small ( ⁇ 80 ⁇ ngstrom but preferably ⁇ 50 ⁇ ngstrom), the emission light of the donor dye X will excitate the acceptor dye Y.
- FIG. 2 is a schematic drawing of the closely interacting proteins A and B recognized by an anti-A and an anti-B antibody.
- Probe A is conjugated with donor dye X and probe B with acceptor dye Y. Furthermore, both probes are conjugated with biotin. After incubation with probes A and B, the probes can be bound together via incubation with avidin, provided that the probes indeed recognize and bind to the closely interacting proteins A and B. This juxtaposition of the two antibody probes (stabilized by the biotin-avidin system) is detectable via the FRET principle (see FIG. 1 ).
- the invention now provides a solution for this problem by providing the insight that juxtaposing of probes can be stabilized and/or enhanced by providing at least one probe with a reactive group.
- a set of at least a first and a second molecular probe is provided, each probe provided with a dye wherein the dyes together allow energy transfer; at least one probe comprising a reactive group allowing juxtaposing of the at least first and second probe wherein the reactive group allows to modulate juxtaposing the probes such that there is an increased likelihood of energy transfer between them.
- Use of such a probe set yields an improved sensitivity of detecting juxtaposed probes by measuring energy transfer compared to use of probes without a reactive group.
- the term “reactive group” refers to a moiety which allows modulating the spatial organization of FRET dyes on the probes such that there is an increase in the probability of energy transfer to occur and/or an increase in energy transfer efficiency.
- the spatial organization refers to both the distance between the dyes as well as to their relative orientation. Modulating the spatial organization includes adjusting and stabilizing the spatial organization of dyes.
- One of the primary conditions for energy transfer to occur is that donor and acceptor molecules must be in close proximity, typically 2-100 ⁇ .
- a reactive group allows bringing the dyes within a distance of 100 ⁇ of each other, more preferably within 50 ⁇ of each other but most preferably within a distance of 20 ⁇ of each other. It is therefore preferred that a reactive group is small, like smaller than 10 kiloDalton (kD), better smaller than 5 kDa, even better smaller than 2 kDa or best smaller than 1 kDa.
- a reactive group may be capable of modulating juxtaposed probes (probes bound via their binding domains to interacting molecules) such that there is an increased likelihood of energy transfer between dyes by directly interacting with another probe.
- a reactive group of a first probe binds to a part of a juxtaposed second probe to form a stable complex between the probes in a spatial orientation that is favorable for FRET to occur.
- the site of modification is mainly determined by the presence and accessibility of a certain residue via which a reactive group is conjugated to a probe, e.g. via primary amines or via thiol groups.
- an antibody probe may contain a reactive group at either the constant and/or the variable region of the immunoglobulin. It is conceivable that not every site is equally suitable for interacting with a second probe, for instance, due to steric hindrance. Therefore, it is preferred that a probe is provided with a multiplicity of reactive groups to statistically increase its capacity to interact with another probe.
- a method for detecting at least two interacting molecules in a cell using a set of at least a first and a second molecular probe, each probe capable of binding to a different molecule, each probe further provided with a dye wherein the dyes together allow energy transfer, at least one probe provided with a reactive group allowing to modulate juxtaposing the at least first and the second probe such that there is an increased likelihood of energy transfer between the dyes comprising: providing a set of probes, providing a sample comprising a cell, contacting the sample with the probes under conditions that allow juxtaposing of the probes on the interacting molecules, removing any unbound and any non-specifically bound probe and detecting juxtaposition of the probes via FRET to determine the interaction between the molecules.
- a first probe can bind directly to at least a second probe
- a set of probes A and B are used to detect an interaction between molecule A and B in a sample.
- the sample is contacted with probe A comprising a reactive group to allow recognition of and binding to molecule A.
- any unbound and any non-specifically bound probe A is removed by repeated washing steps.
- the sample is contacted with probe B specifically reactive with molecule B under conditions allowing juxtaposing of probe A and B on interacting molecules A and B.
- any unbound and any non-specifically bound probe B may be removed by repeated washing steps.
- a reactive group of probe A may interact with a juxtaposed probe B to modulate the spatial orientation of the dyes present on the probes such that there is an increased likelihood of energy transfer between them.
- this method can be used to detect closely interacting molecules, it shall be clear that such a procedure, involving multiple separate contacting and washing steps, is rather laborious and time-consuming.
- probes are capable of directly interacting with each other, a significant background signal can be expected because, generally speaking, specific probes bind to their target molecules irrespective of whether these molecules interact.
- a probe A bound to molecule A not interacting with molecule B might still recruit probe B and allow energy transfer between dyes conjugated to probes A and B.
- probe A is efficiently removed following contacting the sample with probe A
- an unwanted interaction between probe A and B can occur upon subsequent contacting the sample with probe B. Both events may result in a detectable energy transfer signal despite the fact that probe B is not juxtaposed to probe A on interacting molecules.
- a reactive group of at least a first probe is not directly or immediately reactive with a second probe in order to avoid self association of the probes.
- This is also advantageous for an optimal recognition of interacting molecules by the binding domain of each probe and for juxtaposing the probes on the molecules. Moreover, it avoids untimely energy transfer to occur between directly connected or multimerized probes and decreases an aspecific background signal. This is important to ensure that an energy transfer signal truly reflects juxtaposed probes.
- the invention provides the insight that a probe comprising a reactive group which does not directly interact with another probe to avoid self association of the probes, is advantageously used in a system comprising a so-called “bridging” substance capable of mediating an interaction between the probes.
- a system comprising a so-called “bridging” substance capable of mediating an interaction between the probes.
- Such a system allows to modulate juxtaposing the probes such that there is an increased likelihood of energy transfer between the dyes on the probes while minimizing the chance of aspecific and/or untimely interactions between probes.
- Use of such a set of probes in combination with a bridging substance has several advantages over use of directly interacting probes. First, an improved specificity and reduced background staining can be achieved.
- probes need to be in a close juxtaposition of each other prior to the addition of the substance i.e. resulting from binding of one probe adjacent to another probe on closely interacting molecules.
- the procedure is faster and easier because no separate contacting steps and washing steps are required for each individual probe. Thus, it permits to contact a sample with a mixture of probes all together in a single action. Likewise, any unbound and any non-specifically bound probes can be removed simultaneously.
- a substance may be any kind of compound capable of binding to or modifying a probe, a reactive group and/or a dye to modulate the spatial organization of dyes on juxtaposed probes such that it is favorable for FRET.
- the substance allows bringing the dyes within a distance of 2 to 100 ⁇ ngstrom to each other.
- the substance is preferably added to a sample following binding of dye-conjugated probes to interacting molecules, in an amount effective to modulate the spatial organization of the dyes on juxtaposed probes.
- the substance binds to a reactive group with a high specificity and a high affinity. Also, it is preferred that such a substance is relatively small so that the bridging substance only minimally affects the distance between a pair of dyes and the relative orientation of a pair of dyes.
- each probe provided with a dye wherein the dyes together allow energy transfer; each probe provided with a reactive group.
- a substance is preferably capable of binding, or “bridging”, at least two reactive groups.
- each probe within a set of probes is provided with the same reactive group.
- each probe within a set of probes may be provided with a different reactive group but having the same reactivity. This allows the use of one type of bridging substance having at least two identical binding sites for a reactive group.
- a probe is provided with a multiplicity of reactive groups, like two or three or even up to ten reactive groups, enabling the probe to interact with more than one molecule of bridging substance. Providing a probe with more than one reactive group will theoretically increase the likelihood of an interaction between the probe and a bridging substance. Furthermore, for the ease of practicing the present invention, a suitable reactive group or a derivative thereof is commercially available and can be easily and efficiently attached to a probe.
- a particularly interesting reactive group is biotin, with avidin or streptavidin being a particularly suitable bridging substance.
- Avidin is an egg-white derived glycoprotein with a molecular weight of about 68000 daltons and a diameter of 8 to 10 ⁇ ngstrom. It consists of four identical subunit chains.
- One avidin or streptavidin molecule can bind four molecules of biotin.
- Avidin has an extraordinarily high affinity (affinity constant>10 15 M-1) for biotin. This high affinity assures the user of a rapidly formed and stable complex between avidin and the biotin-labeled probes.
- the protein streptavidin produced by the bacterium Streptomyces avidinii , has a structure very similar to avidin, and also binds biotin tightly. It often exhibits lower non-specific binding, and thus is frequently used in place of avidin. Once a biotin-avidin complex forms, the bond is essentially irreversible.
- the biotin-avidin system is widely used and has proven to be very useful in the detection and localization of antigens, glycoconjugates, and nucleic acids by employing biotinylated antibodies, lectins, or nucleic acid probes. As said, a reactive group with such a small size is advantageous for achieving a close distance between a dye pair.
- Biotin is a vitamin with a molecular weight of only 244 daltons. Furthermore, many biotin molecules can be coupled to a protein, enabling a biotinylated probe to bind more than one molecule of avidin. Avidin, streptavidin and biotin are available from many commercial sources. Various standard procedures for preparing biotin-conjugates are known to those skilled in the art, most of which can be completed within a day. Moreover, commercial biotinylation kits are available which contain all the necessary components for protein biotinylation.
- a suitable substance comprises a molecule capable of binding at least one of each reactive group.
- a binding substance comprises a complex of at least two molecules that can be covalently or non-covalently attached to each other, wherein each molecule is capable of binding to a reactive group.
- a method according to the invention allows detection of at least two interacting molecules in a cell wherein at least one of the molecules is a proteinaceous substance.
- at least one of the molecules is a nucleic acid.
- at least one of the molecules is a lipid or a carbohydrate.
- the invention provides a method to detect the interaction of at least one protein with at least one nucleic acid, such as a DNA-binding protein binding to a specific DNA conformational sequence.
- the family of DNA-binding molecules includes transcriptional activators or repressor proteins as well as other proteins which bind to double- and/or single-stranded DNA. It also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
- RNA-binding proteins are required for translation regulation of gene expression. They are involved in multiple post-translational processes such as the regulation of pre-mRNA splicing, mRNA stability and transport of RNAs between nucleus and cytoplasm.
- a probe may be used which binds to an RNA-binding protein, like an antibody against a certain splicing factor, in combination with a second probe which recognizes a specific RNA sequence.
- a FRET signal is produced only when an interaction takes place between the splicing factor and the RNA.
- the method provided permits detection of a protein-nucleic acid interaction at the single cell level. To avoid interference with an interaction between molecules of interest, it is preferred that the binding domains of the probes recognize and bind to a region of the molecules of interest that is distinct from the site of interaction between the molecules.
- probes which can detect the interaction between a protein, such as a carbohydrate binding protein (CBP), and a carbohydrate.
- CBP carbohydrate binding protein
- Protein-carbohydrate interactions are now recognized to be important mediators of cell communication.
- CBPs recognize carbohydrate ligands on glycoproteins and glycolipids. Included are four large families of CBPs, the siglecs, C-type lectins, galectins and the subset of T cell antigen receptors (TCR) that recognize carbohydrate ligands presented by CD1 and MHC antigen presenting molecules.
- TCR T cell antigen receptors
- the present invention concerns a probe set that can be used for the detection of a protein-lipid interaction, at least one probe being reactive with a protein of interest and at least one probe being reactive with a lipid of interest.
- the protein may be an enzyme, such as a lipase, a lipid kinase or a lipid phosphatase, interacting with a lipid substrate.
- the protein probe may comprise an antibody specifically reactive with the protein.
- a lipid probe according to the invention can be a protein moiety with lipid binding properties.
- lipid probes which specifically recognize and bind to a lipid molecule which is involved in signal transduction pathways, like phosphoinositide polyphosphates or lipid second messengers diacylglycerol (DAG) or phosphatidic acid (PA).
- DAG diacylglycerol
- PA phosphatidic acid
- PH phosphoinositide polyphosphates
- a suitable lipid probe includes a recombinantly produced and purified PH domain.
- PDC protein kinase C
- PA binding region of Raf-1 kinase.
- a lipid probe comprises an antibody directed against a specific lipid, like a monoclonal antibody specifically reactive with PtdInsP(3). 10 But other lipid probes can be thought of as well.
- a set of dye-conjugated probes according to the invention can be used to detect a wide variety of various signal transduction events, either stable or transient, at the single cell level. These include the interaction of a receptor with one or more other molecules, like receptor-ligand interaction, receptor clustering or multimerization, the interaction of a receptor with an intracellular signaling molecule. Other events to be detected using a method provided herein comprise interaction of various signaling molecules with each other, like the docking of a Src-homology 2 (SH2)-containing protein to a specific phosphotyrosine residue in another protein, or the binding of a Src-homology 3 (SH3)-containing protein to proline-rich stretch in another protein.
- SH2 Src-homology 2
- SH3 Src-homology 3
- the present method permits to detect interactions between cytoskeletal proteins as well as between nuclear proteins (in the so-called signalosome).
- Activation of a signal transduction pathway often includes protein phosphorylation by tyrosine kinases and/or serine/threonine kinases. Protein phosphorylations can change enzyme activities and protein conformations. The eventual outcome is an alteration in cellular activity and changes in the program of genes expressed within the responding cells.
- a probe comprises a phospho-specific antibody which specifically recognizes a protein in its phosphorylated state.
- a phosphorylated residue may be a tyrosine, serine or threonine residue.
- Phosphospecific antibodies against a wide variety of signaling proteins can be obtained from a number of companies such as Upstate Biotechnology, New England Biolabs, Sigma and many others.
- a Cy3-labeled phosphotyrosine-specific antibody against the Erb receptor tyrosine kinase can be used to specifically detect the activated form of the receptor.
- Suitable probes include a phosphospecific antibody that recognizes only the phosphorylated form of the nuclear transcription factor forkhead in rhabdomyosarcoma (FKHR), protein kinase B (PKB), mitogen-activated protein kinase (MAPK).
- FKHR rhabdomyosarcoma
- PBB protein kinase B
- MAPK mitogen-activated protein kinase
- analogs of nucleotides that serve as substrates or inhibitors of enzymes, and derivatives that selectively bind to regulatory sites of nucleotide-binding proteins have been used as structural and mechanistic probes for isolated proteins. These type of molecules also represent interesting probes for practicing a method according to the invention.
- a method provided herein allows detection of interacting molecules at the single cell level.
- Single cells can be analyzed using e.g. flow cytometry or fluorescence microscopy.
- the detection is performed by flow cytometry.
- flow cytometry A major advantage of flow cytometry is that it directly gives quantitative data and that it is very rapid (results can be obtained within a few hours). Detecting energy transfer by flow cytometry allows high throughput analysis of interacting molecules. High throughput flow cytometric detection of molecular interactions at the single cell level allows for time course and dose response studies of one or more of the aforementioned interactions, such as signal transduction events, transcription factor interactions.
- a method provided allows the detection of molecular interaction at the single cell level in permeabilized and/or fixed cells. Furthermore, because the method provided can detect endogenous molecules, it is especially useful to investigate molecular interactions in primary cells. It can for example be used to discriminate between normal and abnormal cells on the basis of one or more of the above-mentioned interactions.
- the current invention is preferably practiced with a donor/acceptor pair that is suitable for FRET detection by flow cytometry.
- a pair commonly used for FRET includes fluorescein isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC).
- FITC fluorescein isothiocyanate
- TRITC tetramethylrhodamine isothiocyanate
- the sensitivity is poor because of the relatively low molar extinction coefficient and low quantum yield for FITC and TRITC.
- laser sources for this pair are usually not found on standard flow cytometers. These problems are not encountered when using the R-phycoerythrin (R-PE)/Allophycocyanin (APC) pair.
- R-PE R-phycoerythrin
- APC Allophycocyanin
- Phycobiliproteins are produced naturally and are associated with phycobilisomes and are used by different cyanobacteria or algea.
- the PE/APC pair is very promising because 90% of FRET efficiency may be reached in spite of the sizes of PE and APC. Furthermore, this FRET pair can be detected easily on commercially available flow cytometers such as FACSCalibur, LSR, and. FAGSVantage equipped with two common lasers (or a diode) in a configuration emitting at 488 and 632 nm.
- Detection of energy transfer using flow cytometry or fluorescence activated cell sorting offers the possibility to perform rapid, multiparametric analysis of specific individual cells in a heterogeneous population.
- the detection of multiple fluorescent markers on a cell by flow cytometry provides a powerful tool for single cell analysis and allows subset gating of a target cell population. Selective analysis within a target cell population increases sensitivity of the detection method.
- a method according to the invention can include intracellular staining or staining of a surface marker to define a target cell population in a mixture of cells comprising staining with a fluorescent marker antibody capable of selectively identifying the cellular marker.
- the present method flow allows gating of subset of cells that are present in a mixture of cells via immunophenotypic characteristics, i.e. it permits the detection of interacting molecules in a rare population of cells.
- a method is provided to identify and/or isolate rare single cells using multiparameter flow cytometry/cell sorting techniques and to characterize molecular interaction at the single-cell level.
- a method provided now allows detection of interacting molecules in a mixture of abnormal cells with normal cells to identify and quantitate abnormal cells based on the basis of an aberrant interaction between molecules. Such a method is particularly suited for application to a number of important problems in immune system development, infectious diseases, cancer and gene therapy.
- cell prior to staining a cell sample with a probe set, cell are labeled with at least one relevant dye-conjugated antibody according to standard procedures in order to define a target cell population in a mixture of cells.
- a mixture of cells comprises living cells.
- a method comprising staining a sample for at least one cellular marker to define a target cell population comprising contacting the sample with a compound capable of selectively binding to a cellular marker.
- a compound capable of selectively binding to a cellular marker.
- such a compound is directly tagged with a fluorescent dye.
- a suitable compound comprises a fluorescently labeled antibody or a binding fragment functionally equivalent thereto.
- a compound capable of selectively binding to a cellular marker can be used which can be detected using a dye-conjugated secondary reagent (e.g. a fluorescently labeled secondary antibody).
- a cellular marker comprises any kind of intracellular or membrane-bound marker which can be used to distinguish a subpopulation of cells in a mixture of cells.
- a cellular marker can be a cluster of differentiation (CD) antigen.
- CD markers are cell surface molecules of among others haemopoietic cells that are distinguishable with monoclonal antibodies.
- Haemopoietic cells comprise thymocytes, dendritic cells, Langerhans' cells, neutrophils, eosinophils, germinal centre B cells, follicular dendritic cells, plasma cells and bone-marrow cells.
- suitable cellular markers comprise CD1, CD3, CD4, CD8, CD10, CD19, CD20, CD33, CD34 and CD117.
- Monoclonal antibodies directed against a large number of human CD markers can be obtained from various suppliers, such as BD Biosciences or Ancell Immunology Research Products, Bayport, USA. Often, antibodies are available that are directly conjugated with a fluorochrome of choice, for example, CD10-PE or CD19-FITC, which is obviously the preferred choice to practice a method according to the invention.
- a FRET probe set according to the invention can be combined with one or more dyes to mediate leukocyte subset gating via immunophenotypic characteristics, for example, CD10, CD19 and CD20 to accurately define subsets of precursor-B-cells in bone marrow, or CD1, CD4 and CD8 to define subsets of thymocytes, or CD34 and/or CD117 to identify stem/precursor cell populations.
- the invention provides a method for detecting at least two interacting intracellular molecules using of a set of probes according to the invention, each probe being reactive with a different molecule comprising providing a sample comprising a cell, whereby the sample will be subject to fixation and permeabilization, contacting the preparation with a set of probes each probe capable of binding to a specific molecule under conditions that allow juxtaposing of the probes on the molecules, removing any unbound and any non-specifically bound probe and. detecting juxtaposition of the probes via FRET.
- the sample is preferably treated so as to obtain a preservation of the morphology of the material and permeabilization in order to ensure sufficient accessibility of a molecule of interest to a probe.
- fixation may be carried out with a fixative such as formaldehyde.
- the method is practiced to detect intracellular molecules that are positioned within a very short distance of each other, for example within 100 ⁇ ngstrom, preferably within 50 ⁇ ngstrom, more preferably within 20 ⁇ ngstrom.
- a method is provided wherein a sample comprises a primary cell that is obtained from a biological sample.
- a biological sample can be a body fluid sample including blood, bone marrow, urine, cerebrospinal fluid (CSF), saliva. It may also be a tissue sample or a tissue homogenate.
- a sample comprises a cultured cell which may be a cultured primary cell, for example a cultured dermal fibroblast obtained from a skin biopsy.
- a sample may comprise a cultured cell from an established laboratory cell line, like a HeLa, COS, MCF-7 or a Jurkat cell line, which can be obtained from a number of sources such as the American Type Culture Collection (ATCC; see www.atcc.org for an online catalog).
- ATCC American Type Culture Collection
- the invention provides a method to prepare a probe set, comprising contacting each probe with a suitable dye or a derivative thereof to form a conjugate between the probe and the dye and purifying the conjugate from excess dye further comprising contacting at least one probe with a suitable reactive group or a derivative thereof to form a conjugate between the probe and the reactive group and purifying the conjugate from excess reactive group.
- a probe may comprise a conventional (poly- or monoclonal) or a synthetic antibody or other binding molecule, a nucleic acid binding probe, a peptide nucleic acid probe capable of hybridizing to a specific nucleic acid sequence, a lipid binding molecule, a carbohydrate binding molecule.
- the present invention is advantageously carried out using probes with minimal negative steric effects on energy transfer efficiency between dyes attached to the probes.
- an antibody probe smaller than a complete IgG such as a Fab′, Fab, a single chain Fv fragment or a diabody (scFv dimer) may advantageously be used.
- a low molecular weight fluorescent FRET pair can be used.
- the most convenient and widely used functional group for the labeling of biological molecules is a primary amino group. This can be provided by the epsilon-amino group of a lysine residue, or the free N-terminus of a peptide/protein.
- oligonucleotides it is possible to introduce primary amine containing modifier groups during automated synthesis of, for example, oligonucleotides.
- Stable active esters of fluor labeling species that may be stored as solid materials, in particular N-hydroxysuccinimide (NHS) esters have been extensively used over many years for the acylation of such amino groups.
- N-hydroxysuccinimide (NHS) esters have been extensively used over many years for the acylation of such amino groups.
- thiol containing groups such as those contained in cysteine residues or, as with primary amino groups, those introduced as modifiers during automated synthesis (of for example oligonucleotides) can be specifically targeted by maleimide labeling reagents (for example of Cy3 and Cy5). It is not always feasible to consider the use of either primary amino or thiol labeling on all biological molecules.
- a further common route for labeling of, for example, carbohydrate species is via an aldehyde group targeted by hydr
- a commercial kit may suitably be used for obtaining a probe set comprising at least two probes, each probe provided with a dye and additionally provided with a reactive group.
- labeling and purifying probe conjugates with such labeling kits can be readily accomplished in under three hours, with very little hands-on time.
- a kit available for labeling a proteinaceous probe e.g. an antibody or a peptide
- a fluorescent dye www.probes.com/handbook/tables/157Q.html.
- the amount of dye necessary for the desired proteinaceous sample is calculated using the guidelines outlined in the kit's protocol.
- a reactive dye has a succinimidyl ester moiety that reacts efficiently with primary amines of a proteinaceous substance to form a stable dye—conjugate. Purification of a conjugate can be easily accomplished using a spin column or a size-exclusion spin column. The final coupling ratio can be determined according to standard procedures known to those skilled in the art. A dye to protein ration of approximately 2.5 to 1 often results in the retention of the ability of the probe to specifically recognize a molecule and in sufficient fluorescence for use of the FRET technique. Likewise, various commercial kits are available which can be used for labeling a probe with a reactive group, such as biotin.
- the biotin-XX sulfosuccinimidyl ester (SSE) is water soluble and reacts with a primary amine to form a stable biotin conjugate.
- the biotin-XX SSE has a 14-atom spacer that enhances the binding of biotin derivatives to avidin's relatively deep binding sites.
- a labeling kit typically contains a ready-to-use spin column for purification of a biotinylated probe from excess reagents.
- the invention also provides a diagnostic test kit for the determination of interacting molecules in a biological sample comprising a set of probes according to the invention.
- the test kit provided comprising a probe set for FRET-mediated detection of interacting molecules is combined with one or more dye-conjugated antibodies that can be used for defining a target cell population within a mixture of cells.
- the sample comprises a biological sample. For example, it permits identification and quantification of abnormal cells in a mixture of abnormal cells with normal cells, e.g. on the basis of defined abnormal signaling complexes. Many different types of abnormal signaling complexes can be detected in diagnostic applications using a method according to the invention.
- a method as provided herein provides means for monitoring, optionally at the single cell level, normal and pathological Wnt signaling, e.g. in colon carcinomas, melanomas, prostate cancer, breast cancer etc.
- a method or a probe set of the invention is advantageously used in the area of drug discovery, for instance, to select a (candidate) drug compound from among a library of compounds.
- biopharmaceutical companies need a rapid system for screening the target against libraries of compounds to identify those compounds that will have an effect on the target and that demonstrate the potential to become effective drugs.
- a FRET based method of the invention is used to screen for compounds which affect the interaction between two or more molecules in a cell, for instance, compounds that can stimulate or inhibit the formation of signaling complexes such as the signalosome.
- a probe set comprising a first probe that is reactive with a first protein of the signaling complex and a second probe that is reactive with a second protein of the complex.
- the first and second protein interact such that the dye-conjugated probes are juxtaposed and a FRET signal can be detected.
- a compound e.g., a drug candidate molecule
- the interaction between proteins within the complex is disrupted.
- the protein-bound probes are no longer juxtaposed and FRET no longer occurs.
- a similar approach can be undertaken to screen for compounds which stimulate or enhance an interaction between molecules.
- a method as provided herein is used to detect the interaction between a compound (drug) and its target, i.e. the interacting molecules are the compound and the target.
- the interacting molecules are the compound and the target.
- This requires a set of probes wherein one probe is reactive with the compound and another probe that is reactive with the target (protein), for instance a compound-specific antibody probe and a target-specific antibody probe may be used.
- a compound-specific antibody probe and a target-specific antibody probe may be used. It can be imagined that the development of specific antibodies for hundreds of different compounds to be screened is not very attractive in e.g. a high throughput screening setting.
- one may provide different compounds with an identical (epitope) tag such that only one (antibody) probe directed against the tag can be used together with a target-specific probe for detecting the interaction between the compound and its target.
- the invention provides a method for the detection of interacting proteins and other molecules using a set of at least a first and a second probe each probe provided with a dye wherein the dyes together allow energy transfer; at least one probe provided with a reactive group wherein the reactive group allows to modulate juxtaposing of the probes such that there is an increased likelihood of energy transfer between them.
- a probe set according to the invention comprises a set of two dye-conjugated antibodies, each antibody additionally provided with a reactive group.
- an antibody is known to those skilled in the art, e.g. using hybridoma technology or phage display.
- an immunogen such as a recombinant protein or a synthetic peptide.
- the animal's immune response is monitored by taking test bleeds and determining the titer of the reactivity.
- blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the protein can be done if desired. See e.g. Harlow et al. Antibodies. A Laboratory Manual , Cold Spring Harbor Publications, New York (1988).
- Monoclonal antibodies can be obtained by various techniques familiar to those skilled in the art. Antibodies obtained can be characterized conventional immunodiagnostic techniques e.g. by Western blotting using lysates of cells expressing a recombinant fusion protein or by ELISA.
- Biotin is typically conjugated to proteins via primary amines (i.e., lysines). Usually, between 3 and 6 biotin molecules are conjugated to each antibody. Dialyze or exchange over a column the antibody in 100 mM carbonate, pH 8.4. Measure the antibody concentration after buffer equilibration (For IgG, 1 mg/ml has an A(280) of 1.4). If the antibody concentration is less than 1 mg/ml, the conjugation will probably be sub-optimal. If necessary, dilute the antibody to a concentration of 4 mg/ml.
- primary amines i.e., lysines
- Cy5 conjugation of an antibody probe is given but of course many other fluorochromes can be chosen.
- the entire conjugation can typically be performed in about a half-day.
- the reactive Cy5 molecule is unstable. Open a vial, and weigh out the amount you need (typically, 1 or 2 mg is more than enough). Reseal the vial and store under desiccant at 4 degrees Celsius. Immediately dissolve the Cy5 in DMSO at a concentration of 10 mg/ml.
- Cy5 is Covalently Coupled to Primary Amines (Lysines) of the Immunoglobulin.
- Cy5 (Cy5-bis-OSU, N,N′-biscarboxypentyl-5,5′-disulfonatoindodicarbocyanine, Amersham Life Science) in anhydrous DMSO (dimethyl sulfoxide, Aldrich) immediately before use, at a concentration of 10 mg/ml. Do not delay between weighing out the Cy5 and dissolving it in DMSO; likewise, do not delay the addition of the solubilized material to the antibody. For the optimal ratio of 5:1, add 40 ⁇ g Cy5 per mg of antibody; mix immediately. Wrap the tube in foil; incubate and rotate at room temperature for 1 hour.
- DMSO dimethyl sulfoxide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Mathematical Physics (AREA)
- Theoretical Computer Science (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02079667 | 2002-11-07 | ||
EP02079667.8 | 2002-11-07 | ||
PCT/NL2003/000777 WO2004042404A1 (en) | 2002-11-07 | 2003-11-06 | Fret probes and methods for detecting interacting molecules |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2003/000777 Continuation WO2004042404A1 (en) | 2002-11-07 | 2003-11-06 | Fret probes and methods for detecting interacting molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
US20050260660A1 US20050260660A1 (en) | 2005-11-24 |
US7413862B2 true US7413862B2 (en) | 2008-08-19 |
Family
ID=32309414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/122,776 Expired - Lifetime US7413862B2 (en) | 2002-11-07 | 2005-05-05 | FRET probes and methods for detecting interacting molecules |
Country Status (11)
Country | Link |
---|---|
US (1) | US7413862B2 (es) |
EP (1) | EP1561114B1 (es) |
JP (1) | JP4511363B2 (es) |
CN (1) | CN1735808A (es) |
AT (1) | ATE394677T1 (es) |
AU (1) | AU2003283860B2 (es) |
CA (1) | CA2505515C (es) |
DE (1) | DE60320828D1 (es) |
ES (1) | ES2306900T3 (es) |
NZ (1) | NZ540219A (es) |
WO (1) | WO2004042404A1 (es) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010085514A1 (en) | 2009-01-22 | 2010-07-29 | Celladon Corporation | Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium atpase and phospholamban |
WO2012078906A2 (en) | 2010-12-10 | 2012-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes |
US9803017B2 (en) | 2013-07-05 | 2017-10-31 | University Of Washington Through Its Center For Commercialization | Soluble MIC neutralizing monoclonal antibody for treating cancer |
US10281476B2 (en) | 2013-12-10 | 2019-05-07 | Regents Of The University Of Minnesota | Methods to identify modulators of RyR calcium channels |
US10794898B2 (en) | 2014-01-17 | 2020-10-06 | Regents Of The University Of Minnesota | High-throughput, high-precision methods for detecting protein structural changes in living cells |
US11656221B2 (en) | 2019-06-11 | 2023-05-23 | Regents Of The University Of Minnesota | Methods to identify modulators of actin-binding proteins |
US11726081B2 (en) | 2019-02-15 | 2023-08-15 | Regents Of The University Of Minnesota | Methods to identify modulators of tau protein structure |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60320828D1 (de) | 2002-11-07 | 2008-06-19 | Univ Erasmus | Fret proben und verfahren zur erkennung aufeinander einwirkeneden moleküle |
EP1634603A1 (de) * | 2004-08-26 | 2006-03-15 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von transformierten oder infizierten biologischen Zellen |
KR100704011B1 (ko) | 2005-02-16 | 2007-04-04 | 한국과학기술원 | 금속나노입자와 양자점의 fret에 의한 생체분자특이결합 검출 방법 |
JP4639935B2 (ja) * | 2005-05-09 | 2011-02-23 | ソニー株式会社 | 物質間の相互作用を検出する表面、dnaチップその他のセンサーチップ、プローブ、並びにバックグラウンドノイズ蛍光の低減方法 |
EP1900822B1 (en) | 2005-05-24 | 2016-02-03 | Suzuki, Miho | Method for simultaneous analysis of multiple biological reactions or changes in in vivo conditions |
JP5102772B2 (ja) * | 2005-11-29 | 2012-12-19 | ザ・ユニバーシティ・オブ・シドニー | デミボディ:二量体化活性化治療剤 |
KR100878980B1 (ko) | 2005-12-31 | 2009-01-14 | 성균관대학교산학협력단 | Dna에 결합된 염료 수용체와 qd 공여체로 구성된신규한 fret 시스템 |
WO2007125822A1 (ja) * | 2006-04-28 | 2007-11-08 | Tokyo Institute Of Technology | 薬剤スクリーニングのための複合体 |
DK2064348T3 (da) * | 2006-09-18 | 2012-05-29 | Ensemble Therapeutics Corp | Profilering af receptorfamilie |
CA2693055C (en) * | 2007-07-09 | 2012-02-21 | Fio Corporation | Systems and methods for enhancing fluorescent detection of target molecules in a test sample |
WO2009021026A1 (en) * | 2007-08-06 | 2009-02-12 | University Of Kentucky Research Foundation | Semi-synthetic antibodies as recognition elements |
BRPI0819739A2 (pt) * | 2007-11-21 | 2017-05-09 | Univ Erasmus Med Ct Rotterdam | sondas de fret otimizadas e usos das mesmas |
US8180421B2 (en) * | 2007-12-12 | 2012-05-15 | Kimberly-Clark Worldwide, Inc. | Resonance energy transfer based detection of nosocomial infection |
EP2211178A1 (en) * | 2009-01-22 | 2010-07-28 | Universität Potsdam | Method for detecting an analyte in a sample by multiplexing FRET analysis and kit |
CN101638579B (zh) * | 2009-08-21 | 2013-03-06 | 天津城市建设学院 | 量子点-花菁染料-叶酸生物探针及其制备方法 |
DE102010010052A1 (de) * | 2010-03-03 | 2011-09-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Signalgebende Bindemoleküle, Vorrichtungen und Verfahren zu deren Verwendung |
CN103026205B (zh) * | 2010-07-26 | 2016-03-23 | 奥林巴斯株式会社 | 使用发光探针检测溶液中稀疏颗粒的方法 |
WO2012032981A1 (ja) | 2010-09-10 | 2012-03-15 | オリンパス株式会社 | 単一発光粒子の光強度を用いた光分析方法 |
JP5893564B2 (ja) | 2010-09-10 | 2016-03-23 | オリンパス株式会社 | 複数の波長帯域の光計測を用いた光分析方法 |
CN103210302B (zh) | 2010-10-19 | 2015-05-27 | 奥林巴斯株式会社 | 观测单个发光粒子的偏振特性的光分析装置、光分析方法 |
JP5945506B2 (ja) | 2010-11-25 | 2016-07-05 | オリンパス株式会社 | 単一発光粒子の光の波長特性を用いた光分析装置及び光分析方法 |
JP5856983B2 (ja) | 2011-01-20 | 2016-02-10 | オリンパス株式会社 | 単一発光粒子からの光の検出を用いた光分析方法及び光分析装置 |
CN103339256B (zh) | 2011-01-26 | 2016-03-16 | 奥林巴斯株式会社 | 鉴别核酸分子多态性的方法 |
EP2669663B1 (en) | 2011-01-26 | 2017-09-27 | Olympus Corporation | Method for identifying polymorphism of nucleic acid molecules |
WO2012133292A1 (ja) | 2011-03-29 | 2012-10-04 | オリンパス株式会社 | 単一発光粒子検出を用いた光分析装置、光分析方法並びに光分析用コンピュータプログラム |
WO2012141019A1 (ja) | 2011-04-13 | 2012-10-18 | オリンパス株式会社 | 単一発光粒子検出を用いた光分析装置、光分析方法及び光分析用コンピュータプログラム |
WO2012144528A1 (ja) | 2011-04-18 | 2012-10-26 | オリンパス株式会社 | 標的粒子の定量方法、光分析装置及び光分析用コンピュータプログラム |
JP6013335B2 (ja) | 2011-08-11 | 2016-10-25 | オリンパス株式会社 | 標的粒子の計数方法 |
WO2013024650A1 (ja) | 2011-08-15 | 2013-02-21 | オリンパス株式会社 | 単一発光粒子検出を用いた光分析装置、光分析方法及び光分析用コンピュータプログラム |
JP6010033B2 (ja) | 2011-08-26 | 2016-10-19 | オリンパス株式会社 | 光分析を用いた単一粒子検出装置、単一粒子検出方法及び単一粒子検出用コンピュータプログラム |
CN103765196B (zh) | 2011-08-26 | 2016-03-02 | 奥林巴斯株式会社 | 利用单个发光粒子检测的光分析装置及光分析方法 |
EP2752655A4 (en) | 2011-08-30 | 2015-06-17 | Olympus Corp | PROCEDURE FOR DETECTING TARGET PARTICLES |
CN103765197B (zh) | 2011-08-30 | 2016-03-02 | 奥林巴斯株式会社 | 利用单个发光粒子检测的光分析装置、光分析方法以及光分析用计算机程序 |
CN103930768B (zh) | 2011-11-10 | 2016-05-18 | 奥林巴斯株式会社 | 利用单个发光粒子检测的光分析装置、光分析方法以及光分析用计算机程序 |
RS56773B1 (sr) * | 2012-01-13 | 2018-04-30 | Univ Wuerzburg J Maximilians | Dvojna bipartitna funkcionalna komplementacija izazvana antigenom |
WO2013121905A1 (ja) | 2012-02-17 | 2013-08-22 | オリンパス株式会社 | 単一粒子検出を用いた光分析装置、光分析方法及び光分析用コンピュータプログラム |
JP5940644B2 (ja) | 2012-02-22 | 2016-06-29 | オリンパス株式会社 | 標的粒子の検出方法 |
WO2013140890A1 (ja) | 2012-03-21 | 2013-09-26 | オリンパス株式会社 | 標的核酸分子の検出方法 |
EP2840381B1 (en) | 2012-04-18 | 2017-08-09 | Olympus Corporation | Method for detecting target particles |
EP2840380A4 (en) | 2012-04-18 | 2015-11-25 | Olympus Corp | SINGLE PARTICLE DETECTOR WITH PHOTO ANALYSIS, SINGLE PARTICLE PROCESSING AND COMPUTER PROGRAM FOR SINGLE PARTICLE DETECTION |
JP6360481B2 (ja) | 2013-07-31 | 2018-07-18 | オリンパス株式会社 | 単一発光粒子検出技術を用いた光学顕微鏡装置、顕微鏡観察法及び顕微鏡観察のためのコンピュータプログラム |
JP6313776B2 (ja) | 2013-10-07 | 2018-04-18 | オリンパス株式会社 | 単一発光粒子検出を用いた光分析装置、光分析方法及び光分析用コンピュータプログラム |
CN104592396A (zh) * | 2015-02-26 | 2015-05-06 | 南京大学 | 基于荧光共振能量转移技术的Caspase-8活性检测荧光探针 |
US10900070B2 (en) | 2015-05-01 | 2021-01-26 | The General Hospital Corporation | Multiplex analysis of gene expression in individual living cells |
KR101997241B1 (ko) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
WO2017098597A1 (ja) | 2015-12-09 | 2017-06-15 | オリンパス株式会社 | 単一発光粒子検出を用いた光分析方法及び光分析装置 |
WO2017132574A1 (en) * | 2016-01-29 | 2017-08-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for screening pediatric gliomas and methods of treatment thereof |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US10544221B2 (en) | 2016-05-20 | 2020-01-28 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
BR112019010602A2 (pt) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | proteínas trispecíficas para psma e métodos de uso |
WO2018098354A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
EP3351926A1 (en) * | 2017-01-18 | 2018-07-25 | Hifibio | Method for analyzing and selecting a specific droplet among a plurality of droplets and associated apparatus |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
US10543271B2 (en) | 2017-05-12 | 2020-01-28 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
US10730954B2 (en) | 2017-05-12 | 2020-08-04 | Harpoon Therapeutics, Inc. | MSLN targeting trispecific proteins and methods of use |
PE20201183A1 (es) | 2017-10-13 | 2020-11-03 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso |
US10927180B2 (en) | 2017-10-13 | 2021-02-23 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
IL297931A (en) | 2018-09-25 | 2023-01-01 | Harpoon Therapeutics Inc | dll3 binding proteins and methods of use |
US11604186B2 (en) * | 2018-10-17 | 2023-03-14 | Molecular Devices (Austria) GmbH | Real time western blot assays utilizing fluorescence resonance energy transfer (FRET) |
CN110243792A (zh) * | 2019-06-11 | 2019-09-17 | 山东师范大学 | 一种基于量子点和四面体dna结构的荧光化学传感器及其检测方法和应用 |
JP2023527609A (ja) | 2020-02-21 | 2023-06-30 | ハープーン セラピューティクス,インク. | Flt3結合タンパク質および使用方法 |
CN116087069B (zh) * | 2023-04-10 | 2023-08-08 | 苏州药明康德新药开发有限公司 | 一种基于流式细胞术检测特定细胞群体组蛋白甲基化和乙酰化修饰水平的方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999018124A1 (en) | 1997-10-07 | 1999-04-15 | Merck & Co., Inc. | Assays for nuclear receptor ligands using fret |
WO2001033199A2 (en) | 1999-11-05 | 2001-05-10 | Isis Innovation Limited | Universal fluorescent sensors |
US6235535B1 (en) | 1996-06-28 | 2001-05-22 | Valtion Teknillinen Tutkimuskeskus | Fluorescent energy transfer ligand interaction assay on a lipid film |
US20020081617A1 (en) | 2000-11-08 | 2002-06-27 | Tione Buranda | Fluorescence and FRET based assays for biomolecules on beads |
US20030059811A1 (en) * | 2001-06-14 | 2003-03-27 | Hakim Djaballah | Methods of screening for ligands of target molecules |
US20030228603A1 (en) * | 2002-04-05 | 2003-12-11 | Cload Sharon T. | Compositions selective for caffeine or aspartame and methods of using same |
EP1382965A1 (en) | 2001-04-23 | 2004-01-21 | Eiken Kagaku Kabushiki Kaisha | Analysis method using reporter (label) intermolecular interaction |
WO2004042404A1 (en) | 2002-11-07 | 2004-05-21 | Erasmus Universiteit Rotterdam | Fret probes and methods for detecting interacting molecules |
US7081336B2 (en) * | 2001-06-25 | 2006-07-25 | Georgia Tech Research Corporation | Dual resonance energy transfer nucleic acid probes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000017655A1 (en) * | 1998-09-18 | 2000-03-30 | Massachusetts Institute Of Technology | Water-soluble fluorescent semiconductor nanocrystals |
US6140054A (en) * | 1998-09-30 | 2000-10-31 | University Of Utah Research Foundation | Multiplex genotyping using fluorescent hybridization probes |
JP2001204497A (ja) * | 2000-01-20 | 2001-07-31 | Japan Science & Technology Corp | 蛍光共鳴エネルギー移動を利用した、dnaハイブリダイゼーション法によるdna検出方法 |
-
2003
- 2003-11-06 DE DE60320828T patent/DE60320828D1/de not_active Expired - Lifetime
- 2003-11-06 NZ NZ540219A patent/NZ540219A/en unknown
- 2003-11-06 CA CA2505515A patent/CA2505515C/en not_active Expired - Fee Related
- 2003-11-06 CN CNA2003801083656A patent/CN1735808A/zh active Pending
- 2003-11-06 AU AU2003283860A patent/AU2003283860B2/en not_active Ceased
- 2003-11-06 WO PCT/NL2003/000777 patent/WO2004042404A1/en active Application Filing
- 2003-11-06 JP JP2004549718A patent/JP4511363B2/ja not_active Expired - Fee Related
- 2003-11-06 EP EP03776064A patent/EP1561114B1/en not_active Expired - Lifetime
- 2003-11-06 ES ES03776064T patent/ES2306900T3/es not_active Expired - Lifetime
- 2003-11-06 AT AT03776064T patent/ATE394677T1/de not_active IP Right Cessation
-
2005
- 2005-05-05 US US11/122,776 patent/US7413862B2/en not_active Expired - Lifetime
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235535B1 (en) | 1996-06-28 | 2001-05-22 | Valtion Teknillinen Tutkimuskeskus | Fluorescent energy transfer ligand interaction assay on a lipid film |
WO1999018124A1 (en) | 1997-10-07 | 1999-04-15 | Merck & Co., Inc. | Assays for nuclear receptor ligands using fret |
WO2001033199A2 (en) | 1999-11-05 | 2001-05-10 | Isis Innovation Limited | Universal fluorescent sensors |
US20020081617A1 (en) | 2000-11-08 | 2002-06-27 | Tione Buranda | Fluorescence and FRET based assays for biomolecules on beads |
EP1382965A1 (en) | 2001-04-23 | 2004-01-21 | Eiken Kagaku Kabushiki Kaisha | Analysis method using reporter (label) intermolecular interaction |
US20040110245A1 (en) | 2001-04-23 | 2004-06-10 | Teruyuki Nagamune | Analysis method using reporter (label) intermolecular interaction |
US20030059811A1 (en) * | 2001-06-14 | 2003-03-27 | Hakim Djaballah | Methods of screening for ligands of target molecules |
US7081336B2 (en) * | 2001-06-25 | 2006-07-25 | Georgia Tech Research Corporation | Dual resonance energy transfer nucleic acid probes |
US20030228603A1 (en) * | 2002-04-05 | 2003-12-11 | Cload Sharon T. | Compositions selective for caffeine or aspartame and methods of using same |
WO2004042404A1 (en) | 2002-11-07 | 2004-05-21 | Erasmus Universiteit Rotterdam | Fret probes and methods for detecting interacting molecules |
Non-Patent Citations (6)
Title |
---|
Bader et al., "A cGMP-Dependent Protein Kinase Assay for High Throughput Screening Based pf Time-Resolved Fluorescence Resonance Energy Transfer," Journal of Biomolecular Screening, 2001, pp. 255-263, vol. 6, No. 4. |
Kane et al., Development of a Binding Assay for p53/HDM2 by Using Homogenous Time-Resolved Fluorescence, Analytical Biochemistry, 2000, pp. 29-38, vol. 278. |
Lundin et al., "Development of a Time-Resolved Fluorescence Resonance Energy Transfer Assay (Cell TR-FRET) for Protein Detection on Intact Cells," Analytical Biochemistry, 2001, pp. 92-97, vol. 299. |
PCT International Preliminary Examination Report, PCT/NL03/00777, dated Jan. 13, 2005. |
PCT International Search Report, PCT/NL03/00777, dated Mar. 5, 2004. |
Szollosi et al., "Application of Fluorescence Resonance Energy Transfer in the Clinical Laboratory: Routine and Research," Cytometry (Communications in Clinical Cytometry), 1998, pp. 159-179, vol. 34. |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010085514A1 (en) | 2009-01-22 | 2010-07-29 | Celladon Corporation | Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium atpase and phospholamban |
WO2012078906A2 (en) | 2010-12-10 | 2012-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes |
US9803017B2 (en) | 2013-07-05 | 2017-10-31 | University Of Washington Through Its Center For Commercialization | Soluble MIC neutralizing monoclonal antibody for treating cancer |
US10281476B2 (en) | 2013-12-10 | 2019-05-07 | Regents Of The University Of Minnesota | Methods to identify modulators of RyR calcium channels |
US10794898B2 (en) | 2014-01-17 | 2020-10-06 | Regents Of The University Of Minnesota | High-throughput, high-precision methods for detecting protein structural changes in living cells |
US11726081B2 (en) | 2019-02-15 | 2023-08-15 | Regents Of The University Of Minnesota | Methods to identify modulators of tau protein structure |
US11656221B2 (en) | 2019-06-11 | 2023-05-23 | Regents Of The University Of Minnesota | Methods to identify modulators of actin-binding proteins |
Also Published As
Publication number | Publication date |
---|---|
DE60320828D1 (de) | 2008-06-19 |
CA2505515C (en) | 2013-08-27 |
JP4511363B2 (ja) | 2010-07-28 |
JP2006505775A (ja) | 2006-02-16 |
CA2505515A1 (en) | 2004-05-21 |
ATE394677T1 (de) | 2008-05-15 |
AU2003283860A1 (en) | 2004-06-07 |
EP1561114A1 (en) | 2005-08-10 |
WO2004042404A1 (en) | 2004-05-21 |
NZ540219A (en) | 2008-08-29 |
ES2306900T3 (es) | 2008-11-16 |
AU2003283860B2 (en) | 2009-09-17 |
CN1735808A (zh) | 2006-02-15 |
EP1561114B1 (en) | 2008-05-07 |
US20050260660A1 (en) | 2005-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7413862B2 (en) | FRET probes and methods for detecting interacting molecules | |
AU2003283860A2 (en) | Fret probes and methods for detecting interacting molecules | |
US7575874B2 (en) | Method and probes for the detection of a tumor specific fusion protein | |
US6492125B2 (en) | Method to assess library X library interactions | |
Sanchez-Carbayo | Antibody arrays: technical considerations and clinical applications in cancer | |
EP1145004B1 (en) | Methods for detecting changes to cellular components | |
AU771927B2 (en) | Multihued labels | |
JP2011505549A (ja) | 改良型fretプローブおよびその使用 | |
Poluri et al. | Experimental methods for determination of protein–protein interactions | |
US20050124008A1 (en) | Homogeneous competition assays | |
Sharma et al. | 9.1 PROTEIN AS CRUCIAL BIOMOLECULES AND ITS LABELLING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ERASMUS UNIVERSITEIT ROTTERDAM, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN DONGEN, JACOBUS J. M.;STAAL, FRANK J. T.;REEL/FRAME:016828/0142;SIGNING DATES FROM 20050623 TO 20050704 |
|
AS | Assignment |
Owner name: ERASMUS UNIVERSITEIT ROTTERDAM, NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VAN DONGEN, JACOBUS J M;STAAL, FRANK J T;REEL/FRAME:019641/0834;SIGNING DATES FROM 20070712 TO 20070713 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |